Lisraya (brepocitinib tosylate)

Where it stands

The US FDA approved Lisraya (brepocitinib tosylate) on 2026-08-27. The sponsor is listed in the records as Priovant Therap, and the application number is NDA220106. The product is an oral tablet.

The records do not state the approved indication or the therapeutic area. They also give no dosing, patient population or label text, so this analysis cannot say which patients may receive the product or under what conditions. The approved prescribing information is the primary source for those details.

Regulatory pathway and designations

Lisraya was reviewed as an NDA and carries two designations in the records: New molecular entity and Priority review. An NME is an active moiety the FDA has not previously approved in the US. Priority review is a review-clock designation given to applications that the FDA judges could offer significant improvements in treatment, diagnosis or prevention of a serious condition. Under the PDUFA framework it shortens the target review timeline compared with standard review.

The records do not give the submission date, filing date or PDUFA goal date, so the actual review duration cannot be calculated. They also do not say whether other expedited programs applied, such as Breakthrough Therapy, Fast Track or Orphan designation, or whether an advisory committee was convened. The CHMP opinion field is blank, and the records show no EU or other non-US regulatory activity.

Safety and pharmacovigilance

The records contain no safety information. They do not describe the label's warnings, any boxed warning, contraindications, a REMS, or postmarketing requirements or commitments. This analysis therefore draws no conclusions about the product's benefit-risk profile.

As a newly approved NME, Lisraya will enter standard US postmarketing surveillance. This includes expedited reporting of serious unexpected adverse drug experiences, periodic safety reporting by the sponsor, and FDA monitoring of spontaneous reports through FAERS. Safety teams should review the approved label's Warnings and Precautions section and any postmarketing study requirements as soon as the documents are available.

What to watch

The first priority is the approved label and the FDA approval package. These should confirm the indication, the patient population, the dosing and monitoring requirements, and any postmarketing obligations. The review documents should also show the basis for approval and the FDA's assessment of safety.

Other items to track are the sponsor's launch and market-access communications, and any filings outside the US, none of which appear in the records. Early postmarketing safety communications and any label updates after launch are also worth monitoring.